Download PDF
Thromb Haemost 1995; 74(01): 036-039
DOI: 10.1055/s-0038-1642649
Colloquium
The Haemophilias-An Update
Schattauer GmbH Stuttgart

AIDS and Hemophilia - Current Issues

Bruce L Evatt
Centers for Disease Control and Prevention, Atlanta, Georgia, USA
› Author Affiliations
Further Information

Publication History

Publication Date:
09 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Chorba TL, Holman RC, Strine TW, Clarke MJ, Evatt BL. Changes in longevity and causes of death among persons with hemophilia A. Am J Hematol 1994; 45: 112-21
    CrossrefPubMedGoogle Scholar
  • 2 Phillips AN, Sabin CA, Elford J. et al. Use of CD4 lymphocyte count to predict long term survival free of AIDS after HIV infection. Br Med J 1994; 309: 309-313
    CrossrefPubMedGoogle Scholar
  • 3 Chiarotti F, Palombi M, Schinaia N, Ghirardini A, Bellocco R. Median time from seroconversion to AIDS in Italian HIV -positivehaemophiliacs: different parametric estimates. Stat Med 1994; 13: 163-175
    CrossrefPubMedGoogle Scholar
  • 4 Aronstam A, Congard B, Evans DI, Gazengel CF, Herberg U, Hill FG, Jones PM, Ljung R, Mauser-Bunschoten EP, Scheibel E. et al. HIV infection in haemophilia-a European cohort. Arch Dis Child 1993; 68: 521-524
    CrossrefPubMedGoogle Scholar
  • 5 Ehmann WC, Eyster ME, Wilson SE, Andes WA, Goedert JJ. Relationship of CD4 lymphocyte counts to survival in a cohort of hemophiliacs infected with HIV. Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1994; 7: 1095-1098
    PubMedGoogle Scholar
  • 6 Eyster MW, Rabkin CS, Hilgartner MW, Aledort LM. et al. Human immunodeficiency virus-related conditions in children and adults with hemophilia: rates, relationshop to CD4 counts, and predictive value. Blood 1993; 81: 828-834
    PubMedGoogle Scholar
  • 7 Telfer P, Sabin C, Devereux H. et al. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Brit J of Haematology 1994; 87: 555-561
    PubMedGoogle Scholar
  • 8 Theorell T, Blomkvist V, Jonsson H. et al. Social support and the development of immune function in human immunodeficiency virus infection. Psychosomatic Med 1995; 57: 32-36
    CrossrefPubMedGoogle Scholar
  • 9 Gregg-Smith SJ, Pattison RM, Dodd CA, Giangrande PL. et al. Septic arthritis in haemophilia. J Bone& Joint Surg Br 1993; 75: 368-370
    PubMedGoogle Scholar
  • 10 Merchan EC, Magallon M, Manso F, Martin-Villar J. Septic arthritis in HIV positive haemophiliacs. Four cases and a literature review. Int Orthop 1992; 16: 302-6
    PubMedGoogle Scholar
  • 11 Brown SA, Majumdar G, Harrington C. et al. Effect of Splenectomy on HIV-related thrombocytopenia and progression of HIV infection in patients with severe haemophilia. Blood Coagul&Fibrinolysis 1994; 5: 393-397
    PubMedGoogle Scholar
  • 12 Leissinger CA, Andes WA. Role of splenectomy in the management of hemophilic patients with human immunodeficiency virus-associated thrombocytopenic purpura. Am J Hematol 1992; 40: 207-209
    CrossrefPubMedGoogle Scholar
  • 13 Lane HC, Laughon BE, Falloon J. et al. Recent advances in the management of AIDS-related opportunistic infections. Ann Intern Med 1994; 120: 945-955
    CrossrefPubMedGoogle Scholar
  • 14 Gallant JE, Moore RD, Chaisson RE. Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med 1994; 120: 932-944
    CrossrefPubMedGoogle Scholar
  • 15 Womtergerst U, Niinivaara-Kreuzer K, Notheis G. et al. High-dose intravenous immunoglobulins in the treatment of adolescent adult HIV- infected hemophiliacs. Clin Investig 1994; 72: 122-126
    CrossrefPubMedGoogle Scholar
  • 16 Mannucci PM, Gringeri A, Savidge G. et al. Randomized double-blind, placebo-controlled trial of twice daily zidovine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1. European-Australian Haemophilia Collaborative Study Group. Brit J Haematol 1994; 86: 174-179
    CrossrefPubMedGoogle Scholar
  • 17 Jason J, Murphy L, Sleeper LA. et al. Immune and serologic profiles of HIV- infected and noninfected hemophilic children and adolescents. Hemophilia Growth and Development Study. Am J Hematol 1994; 46: 29-35
    CrossrefPubMedGoogle Scholar
  • 18 Bray GL, Kroner BL, Aikin S. et al. Loss of high-responder inhibitors in patients with severe hemophia A and human immunodeficiency virus type 1 infection: a report from the Multi-Center Hemophilia Cohort Study. Am J Hematol 1993; 42: 375-379
    CrossrefPubMedGoogle Scholar
  • 19 Gjerset GF, Pike MC, Mosley JW. et al. Effect of low- and intermediate- purity clotting factor therapy on progression of human immunodeficiency virus infection in congenital clotting disorders. Transfusion Safety Study Group. Blood 1994; 84: 1666-1671
    PubMedGoogle Scholar
  • 20 Mannucci PM, Brettler DB, Aledort LM. et al. Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII. The Kogenate Study Group.. Blood 1994; 83: 1958-1962
    PubMedGoogle Scholar
  • 21 Seremetis SV, Aledort LM, Bergman GE. et al. Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects cm immune status. Lancet 1993; 342: 700-703
    CrossrefPubMedGoogle Scholar
  • 22 Smid WM, van derMeer J, Smit JW. et al. The course of preexistent immune abnormalities in HIV negative haemophiliacs treated for two years with a monoclonal purified factor VIII concentrate. ThrombHaemost 1993; 69: 306-310
    PubMedGoogle Scholar
  • 23 Hilgartner MW, Buckley JD, Operskalski EA. et al. Purity of factor VIII concentrates and serial CD4 counts. The Transfusion Safety Study Group. Lancet 1993; 341: 1373-1374
    CrossrefPubMedGoogle Scholar
  • 24 Prowse C. The effects of type of factor VIII concentrate used in haemophilia on T-helper cell number and inhibitor incidence. Blood Coagul Fibrinolysis 1992; 3: 597-604
    CrossrefPubMedGoogle Scholar
  • 25 de Biasi R, Rocino A, Miraglia E. et al. The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virus-infected hemophiliacs: a randomized prospective, two-year comparison with an intermediate purity concentrate. Blood 1991; 78: 1919-1922
    PubMedGoogle Scholar
  • 26 Varon D, Schulman S, Dardik R. et al. High versus ultra-high purity factor VIII concentrate therapy -prospective evaluation of immunological and clinical parameters in HIV seronegative and seropositive hemophiliacs. Thromb Haemost 1994; 72: 359-362
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Mannucci PM, Gringeri A, de Biasi R. et al. Immune status of asymptomatic HIV-infected hemophiliacs: randomized, prospective, two-year comparison of treatment with a high-purity or an intermediate-purity factor VIII concentrate. Thromb Haemost 1992; 67: 310-3
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Hammer SM, Kessler HA, Saag MS. Issues in combination antiretroviral therapy — a review. J Acquir Immune Defic Syndr 1994; 7: S 24-S 37
    PubMedGoogle Scholar
  • 29 Fischl MA, Stanley K, Collier AC. et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1995; 122: 24-32
    CrossrefPubMedGoogle Scholar
  • 30 Zidovudine for the Prevention of HIV Transmission from Mother to Infant.. MMWR 1994; 43: 285-288
    PubMed
  • 31 Ragni MV, Belle SH, Jaffe RA, Duerstein SL, Bass DC. et al. Acquired immunodeficiency syndrome-associated non-Hodgkin’s lymphomas and other malignancies in patients with hemophilia. Blood 1993; 81: 1889-1897
    PubMedGoogle Scholar
  • 32 Anonymous. HIV transmission between two adolescent brothers with hemophilia. MMWR 1993; 42: 948-51
    PubMedGoogle Scholar
  • 33 Brackmann SA, Gerritzen A, Oldenburg J. et al. Search for intrafamilial transmission of hepatitis C vims in hemophilia patients. Blood 1993; 81: 1077-1082
    PubMedGoogle Scholar
  • 34 Ghirardini A, Chiarotti F, Schinaia N. Testing practices and spread of HIV among sexual partners of HIV-positive haemophiliacs in Italy. Gruppo Italiano Coagulopatie Congenite. AIDS 1993; 7: 573-577
    CrossrefPubMedGoogle Scholar
  • 35 Mayes SD, Elsesser V, Schaefer JH. et al. Sexual practices and AIDs knowledge among women partners of HIV-infected hemophiliacs. Public Health Rep 1992; 107: 504-514
    PubMedGoogle Scholar
  • 36 Jacquez Jm, Koopman JS, Simon CP, Longini IM. Role of the primary infection in epidemics of HIV infection in gay cohorts. J Acquir Immune Defic Syndr 1994; 7: 1169-1184
    PubMedGoogle Scholar
  • 37 Dublin S, Rosenberg PS, Goedert JJ. Patterns and predictors of high-risk sexual behavior in female partners of HIV-infected men with hemophilia. AIDS 1992; 6: 475-482
    CrossrefPubMedGoogle Scholar
  • 38 Klimes I, Catalan J, Garrod A. et al. Partners of men with HIV infection and haemophilia: controlled investigation of factors associated with psychological morbidity. AIDS Care 1992; 4: 149-156
    CrossrefPubMedGoogle Scholar
  • 39 Purcell RH, Mannucci PM, Gdovin S. et al. Virology of the Hepatitis A epidemic in Italy. Vox Sang 1994; 67: 2-7
    CrossrefPubMedGoogle Scholar
  • 40 Brackmann HH, Oldenburg J, Eishubinger AM. et al. Hepatitis A vims infection among the hemophilia population at the Bonn Hemophilia Center. Vox Sang 1994; 67: 3-8
    CrossrefPubMedGoogle Scholar
  • 41 Wagner N, Rotthauwe HW. Hepatitis C contributes to liver disease in children and adolescents with hemophilia. Klin Padiatr 1994; 206: 40-44
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Kumar A, Kulkami R, Murray DL. etal. Serologic markers of viral hepatitis A, B, C, and D in patients with hemophilia. J Med Virol 1993; 41: 205-209
    PubMedGoogle Scholar
  • 43 Ragni MV, Ndimibie OK, Rice EO. et al. The presence of hepatitis C vims (HCV) antibody in human immunodeficiency virus-positive hemophilic men undergoing HCV “seroconversion.”. Blood 1993; 82: 1010-1015
    PubMedGoogle Scholar
  • 44 Troisi CL, Hollinger FB, Hoots WK. et al. A multicenter study of viral hepatitis in a United States hemophilic population. Blood 1993; 81: 412-418
    CrossrefPubMedGoogle Scholar
  • 45 Mariani G, Baklaya R. et al. Prospective study of the evaluationof hepatitis C virus infectivity in a high-purity, solvent/detergent- treated factor VIII concentrate: parallel evaluation of other markers for lipid-enveloped and non-lipid-enveloped viruses. The Ad Hoc Study Group of the Fondazione delTEmofilia. Transfusion 1993; 33: 814-818
    CrossrefPubMedGoogle Scholar
  • 46 Rollag H, Patou G, Pattison JR. et al. Prevalance of antibodies against parvovirus B19 in Norwegians with congenital coagulation factor defects treated with plasma products from small donor pools. Scand J Infect Dis 1991; 23: 675-9
    CrossrefPubMedGoogle Scholar